No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Monday, October 27, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

Pfizer battles another Paxlovid lawsuit from Enanta

by TheAdviserMagazine
2 months ago
in Business
Reading Time: 2 mins read
A A
Pfizer battles another Paxlovid lawsuit from Enanta
Share on FacebookShare on TwitterShare on LInkedIn


If you don’t succeed at first, try again – in separate regions. That’s the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent infringement relating to Covid-19 treatment pill Paxlovid (nirmatrelvir/ritonavir).

In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma company infringed on a patent describing protease inhibitors invented by its scientists. Enanta has now followed that up with another filing in Europe, making the same accusation.

Since being emergency authorised in 2021, anti-viral Paxlovid has generated Pfizer more than $26bn in global revenue. This includes a staggering $18.9bn in 2022 when Covid-19 cases were still prevalent. Despite waning demand for Covid-19 treatments, the pill still brought in $1.2bn in 2024, buoyed by government orders.

However, Enanta – known for co-developing hepatitis C virus treatment glecaprevir/pibrentasvir with AbbVie – believes Pfizer designed Paxlovid via unlawful means.

The US biotech stated it is “seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the ’265 Patent) in the manufacture, use and sale of Pfizer’s Covid-19 antiviral, Paxlovid”.

In an emailed statement to Pharmaceutical Technology, a Pfizer spokesperson said: “We are confident in our intellectual property (IP) surrounding Paxlovid and will respond in due course in court.”

The lawsuit, filed in the European Union’s (EU) Unified Patent Court (UPC), targets Pfizer’s commercial activity in the 18 countries of the EU. The company confirmed the ’265 patent in question is the European counterpart of US patent number 11,358,953 (the ’953 Patent) that is the centre of the US lawsuit.

Although it is technically ongoing, Enanta’s US lawsuit hit a major roadblock. In December 2024, a federal judge in Massachusetts sided with Pfizer, granting that the ‘953 patent is invalid. Enanta confirmed at the time it would appeal the decision, adding it “believes strongly in the merits of our case”.

Pfizer reported strong Q2 2025 results this month, bucking a tepid earnings window that gripped the wider pharma industry. Sales for the Paxlovid grew 71% while the Covid-19 vaccine Comirnaty revenue surged 95%.

However, the legal challenge posed by Enanta marks the second issue Pfizer has had to firefight this week. The big pharma company reported a Phase III trial failure for a sickle cell disease candidate purchased as part of a $5.4bn takeover of Global Blood Therapeutics in 2022.

“Pfizer battles another Paxlovid lawsuit from Enanta” was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

 

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.



Source link

Tags: battlesEnantaLawsuitPaxlovidPfizer
ShareTweetShare
Previous Post

Payment Delays Hit 40% of UK Crypto Investors, Banks Point to Fraud

Next Post

Navigate With Confidence The Migration Options For SAP ECC Customers

Related Posts

edit post
Coforge shares rally 6% after Q2 net profit rockets 86% YoY. Should you buy, sell or hold?

Coforge shares rally 6% after Q2 net profit rockets 86% YoY. Should you buy, sell or hold?

by TheAdviserMagazine
October 26, 2025
0

Shares of mid-tier IT services company Coforge rallied 6% to their day's high of Rs 1,867 on Monday, October 27,...

edit post
Milei’s party on track to win Argentina election in big comeback

Milei’s party on track to win Argentina election in big comeback

by TheAdviserMagazine
October 26, 2025
0

President Javier Milei’s party is on track to finish first in Argentina’s midterm vote in early counting, putting the libertarian...

edit post
What Saudi Arabia and Bangladesh can teach Silicon Valley

What Saudi Arabia and Bangladesh can teach Silicon Valley

by TheAdviserMagazine
October 26, 2025
0

The way Saudi entrepreneur Mohammed Aldossary sees it, innovators are animated by the same motivations whether they are in Silicon...

edit post
Here are the major earnings before the open Monday

Here are the major earnings before the open Monday

by TheAdviserMagazine
October 26, 2025
0

Oct. 26, 2025 6:00 PM ETCAJPY, PKX, RVTY, ARLP, CRI, BOH, DQ, DEA, KDPBy: Deepa Sarvaiya, SA News EditorMajor earnings...

edit post
Bed Bath & Beyond Q3 2025 Earnings Preview (BBBY:NYSE)

Bed Bath & Beyond Q3 2025 Earnings Preview (BBBY:NYSE)

by TheAdviserMagazine
October 26, 2025
0

Bed Bath & Beyond (NYSE:BBBY) is scheduled to announce Q3 earnings results on Monday, October 27th, after market close. The...

edit post
49-year-old favorite pizza chain files for Chapter 11 bankruptcy

49-year-old favorite pizza chain files for Chapter 11 bankruptcy

by TheAdviserMagazine
October 26, 2025
0

The pizza restaurant industry is one of the most competitive dining sectors in the U.S., with two pizza giants ranking...

Next Post
edit post
Navigate With Confidence The Migration Options For SAP ECC Customers

Navigate With Confidence The Migration Options For SAP ECC Customers

edit post
Jackson Hole Preview: All Eyes on Powell as Fed Navigates Policy Tightrope

Jackson Hole Preview: All Eyes on Powell as Fed Navigates Policy Tightrope

  • Trending
  • Comments
  • Latest
edit post
77-year-old popular furniture retailer closes store locations

77-year-old popular furniture retailer closes store locations

October 18, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
Another Violent Outburst – Democrats Inciting Civil Unrest

Another Violent Outburst – Democrats Inciting Civil Unrest

October 24, 2025
edit post
Probate vs. Non-Probate Assets: What’s the Difference?

Probate vs. Non-Probate Assets: What’s the Difference?

October 17, 2025
edit post
California Attorney Pleads Guilty For Role In 2M Ponzi Scheme

California Attorney Pleads Guilty For Role In $912M Ponzi Scheme

October 15, 2025
edit post
Dan Hotels buys New York’s Nomo Soho hotel

Dan Hotels buys New York’s Nomo Soho hotel

0
edit post
Southwest Airlines (LUV) Earnings: 3Q25 Key Numbers

Southwest Airlines (LUV) Earnings: 3Q25 Key Numbers

0
edit post
Dell Technologies (DELL) Could Benefit From 2026 Data Center Refresh, Says Piper Sandler

Dell Technologies (DELL) Could Benefit From 2026 Data Center Refresh, Says Piper Sandler

0
edit post
High Dividend 50: Blue Owl Capital Corporation

High Dividend 50: Blue Owl Capital Corporation

0
edit post
The Core Of The Peace Proposal

The Core Of The Peace Proposal

0
edit post
Is It OpenSea or Blur?

Is It OpenSea or Blur?

0
edit post
The Core Of The Peace Proposal

The Core Of The Peace Proposal

October 27, 2025
edit post
Coforge shares rally 6% after Q2 net profit rockets 86% YoY. Should you buy, sell or hold?

Coforge shares rally 6% after Q2 net profit rockets 86% YoY. Should you buy, sell or hold?

October 26, 2025
edit post
Milei’s party on track to win Argentina election in big comeback

Milei’s party on track to win Argentina election in big comeback

October 26, 2025
edit post
HSBC to recognize .1 billion in provision after court ruling in Madoff case

HSBC to recognize $1.1 billion in provision after court ruling in Madoff case

October 26, 2025
edit post
Accel and Prosus team up to back early-stage Indian startups

Accel and Prosus team up to back early-stage Indian startups

October 26, 2025
edit post
What Saudi Arabia and Bangladesh can teach Silicon Valley

What Saudi Arabia and Bangladesh can teach Silicon Valley

October 26, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • The Core Of The Peace Proposal
  • Coforge shares rally 6% after Q2 net profit rockets 86% YoY. Should you buy, sell or hold?
  • Milei’s party on track to win Argentina election in big comeback
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.